SELLAS reports Q1 net loss $11.1M; GFH009 Phase 1 complete in AML, Phase 2a to start

SELLAS Life Sciences Group, Inc.

2023-Q1 EPS reported -$0.47

Net loss $11.1M ($0.47/share) vs $16.7M ($1.05/share) in Q1 2022; cash $23.9M at March 31.
Phase 1 of GFH009 in AML completed; 94% of patients alive, durable remission >6 months; Phase 2a starting Q2.
Phase 3 REGAL study of GPS in AML on track for interim analysis late 2023/early 2024; IDMC OK.
3D Medicines to trigger $13M milestone payments by Q3 2023 via REGAL participation in China.
No licensing revenue in Q1 2023 (vs $1M in Q1 2022); R&D expenses rose to $7.2M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

SELLAS Life Sciences Group, Inc. reported financial results for the quarter ended March 31, 2023.

Period: the quarter ended March 31, 2023
Result: reported results

Exact text from the filing

On May 11, 2023, SELLAS Life Sciences Group, Inc. (“SELLAS”) issued a press release (the “Press Release”) announcing its financial results for the quarter ended March 31, 2023 and providing a corporate update.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

SELLAS Life Sciences Group, Inc. filing history →

Source: SEC EDGAR

accession 0001390478-23-000013

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.